Opinion

Nikhil C. Munshi: Getting MRD as an endpoint was a great partnership between academia and industry and patient organization

Photo of Nikhil C. Munshi taken from www.multiplemyeloma.org

Apr 15, 2024, 12:53

Nikhil C. Munshi: Getting MRD as an endpoint was a great partnership between academia and industry and patient organization

Nikhil C. Munshi, Associate Director of the Jerome Lipper Multiple Myeloma Center at the Dana-Farber Cancer Institute, shared a post on X:

“Getting Minimal Residual Disease (MRD) as an endpoint was a great partnership between academia and industry and patient organization. A model to follow. Patients are three winner.”

Source: Nikhil C. Munshi/X

cancer Dana-Farber Cancer Institute Jerome Lipper Multiple Myeloma Center Minimal Residual Disease MRD Nikhil C. Munshi OncoDaily Oncology partnership

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

One Hand Gives, Another Takes? Trump, Musk, Congress and Childhood Cancer Research Funding

Fabrice André has been elected as the President of the ESMO for the term 2025-2026

Special Coverage